WASHINGTON, June 21 (Reuters) - The U.S. Supreme Court on Monday declined to hear AbbVie Inc’s
(ABBV.N) challenge to a lower court’s decision that it violated federal antitrust law by pursuing a “sham” patent complaint against rival Perrigo Co
(PRGO.N) over AbbVie’s blockbuster testosterone replacement drug AndroGel.
The justices turned away AbbVie's appeal and left intact the lower court's finding that its 2011 complaint against Perrigo was brought solely to delay Perrigo's proposed generic version of AndroGel.
The Philadelphia-based 3rd U.S. Circuit Court of Appeals last year threw out a federal judge's order requiring AbbVie and partner Besins Pharmaceuticals to disgorge $448 million in profits to the Federal Trade Commission, but found that the judge had correctly determined that they had violated antitrust law.